Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/5/2009

nce Call and Webcast on November 5, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

Cadence management will host a conference call on November 5, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing 888-811-5448 (domestic) or 913-312-4376 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance (intravenous acetaminophen), an investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "expects," "anticipates," "plans," "will," and "assuming," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: the company's efforts to accelerate the development of its commercial and supply operations infrastructure, the likelihood of obtaining regulatory approval for Acetavance in a timely manner, or at all, and any financial estimates or projections. The inclusion of forward-looking stateme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... (PRWEB) April 27, 2015 Winscribe ... to their suite of mobile speech productivity technology, ... iOS tablets and smartphones. , Winscribe ... Operating System since 2005. With the latest ... fourth generation mobile application interface in the last ...
(Date:4/27/2015)... Pure n Natural Systems, Inc. is pleased to ... at http://www.purennatural.com/ . The new website includes ... featured and sale items, as well as the official ... n Natural Systems’ website is designed to give customers ... neatly organized and provides plenty of useful information to ...
(Date:4/27/2015)... Aliso Viejo, CA (PRWEB) April 27, 2015 ... directly on top of footage with ProTelestrator from Pixel Film ... to draw a freehand sketch over a moving or still ... broadcasts to diagram and analyze sports plays or incoming weather ... "Animate Mode" checkbox and then adjust the frame slider to ...
(Date:4/27/2015)... Cambia Health Solutions is pleased to ... as Operating Partner within its Direct Health Solutions ... building companies that change the way people experience the ... be responsible for accelerating Cambia’s investments, which are focused ... economically sustainable and person-focused, while looking for new strategic ...
(Date:4/27/2015)... April 27, 2015 Doping has been ... Armstrong and Alex Rodriguez continue to capture the public’s ... a new frontier in performance enhancement along with new ... TV , accomplished neuroscientist Anjan Chatterjee of ... the ethics and dangers of these enhancements in sports. ...
Breaking Medicine News(10 mins):Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 2Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 3Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 4Health News:Pure n Natural Systems, Inc. Launches New Website Design 2Health News:Pure n Natural Systems, Inc. Launches New Website Design 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:Cambia Welcomes Ben Albert as Operating Partner 2Health News:Cambia Welcomes Ben Albert as Operating Partner 3Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3
... Study says surgical advances may explain away the link ... News) -- Cataract surgery doesn,t hasten vision loss in ... conclusion of a new study that challenges the findings ... between cataract surgery and accelerated AMD progression. , AMD ...
... mouse model of human leukemia has provided critical insight into ... myeloid leukemia stem cells. The study, published by Cell Press ... Stem Cell , is likely to have a profound impact ... stem cells. , Leukemia stem cells (LSCs) were initially described ...
... Patient Advocate Foundation (NPAF) -- a national, non-profit organization ... patient access to health care through public policy reform ... Congress for passing and President Obama for signing the ... extend health coverage to four million uninsured American children. ...
... disease, A Su Salud revealed high incidence of diabetes, ... $55 million in free and low cost medical services ... -- CVS/pharmacy, the nation,s leading retail ... Salud" (To Your Health) health fairs, providing free health ...
... Montreal, Canada February 05, 2009 A ... who have received kidney transplants and compares them ... a significantly higher prevalence of psychiatric conditions (depression, ... adolescents who had undergone a transplant. The study ...
... recent survey of in-house,physician recruiters across the country ... on hospital systems throughout the United States, and,recruiting ... the lack,of physicians to fill key provider roles. ... from their most recent recruitment,and retention survey of ...
Cached Medicine News:Health News:Cataract Surgery Doesn't Worsen AMD 2Health News:Leukemia stem cells have more in common with embryonic stem cells than adult stem cells 2Health News:National Patient Advocate Foundation Applauds Congress' and President Obama's Decision to Extend Health Coverage to Four Million Uninsured Children 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Psychological impact found in adolescents with kidney transplants 2Health News:PracticeMatch: Healthcare Survey Defines Physician Recruitment Challenges 2
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)... -- Bayer Corporation hosted its annual "Take Your Child to Work ... headquarters.  This is Bayer,s second "Take Your Child To Work ... campus, and Thursday,s event welcomed 230 children ready to see ... Fortunately, for the kids, this was not just another ... "Science For A Better Life," Bayer made sure that "Take ...
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
Breaking Medicine Technology:Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4
... Calif., March 31, 2011 NewCardio, Inc., (OTC Bulletin ... developer, announced today that the Company has been invited ... performance study at an upcoming conference entitled "Cardiovascular Safety ... Food and Drug Administration (FDA), the Cardiac Safety Research ...
... 31, 2011 The U.S. Department of Energy has ... field of medical technology and innovation for commercializing the ... agency, Dilon and similar entrepreneurs, "build the new industries ... our toughest global challenges." The Dilon 6800® ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator 2
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled double bevel. Blade tip dimension: N/A x 2.65 mm x N/A....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.65 mm x 3.7 mm....
Medicine Products: